Literature DB >> 10825209

Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.

N Nekrep1, N Jabrane-Ferrat, B M Peterlin.   

Abstract

The regulatory factor X (RFX) complex, which contains RFXANK(B), RFXAP, and RFX5, binds to X and S boxes in major histocompatibility complex class II (MHC II) promoters. In the bare lymphocyte syndrome (BLS), which is a human severe combined immunodeficiency, MHC II promoters are neither occupied nor transcribed. Thus, the absence of any one subunit prevents the formation of the RFX complex. Nevertheless, except for a weak binding between RFX5 and RFXAP, no other interactions between RFX proteins have been described. In this study, we demonstrate that RFXANK(B) binds to RFXAP to form a scaffold for the assembly of the RFX complex, which then binds to DNA. Moreover, mutant RFXANK(B) and RFXAP proteins from complementation groups B and D of BLS, respectively, cannot support this interaction. Our data elucidate an intriguing medical situation, where a genetic disease targets two different surfaces that are required for the nucleation of a multisubunit DNA-protein complex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825209      PMCID: PMC85813          DOI: 10.1128/MCB.20.12.4455-4461.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  28 in total

Review 1.  The class II transactivator CIITA is a transcriptional integrator.

Authors:  J D Fontes; S Kanazawa; N Nekrep; B M Peterlin
Journal:  Microbes Infect       Date:  1999-09       Impact factor: 2.700

Review 2.  Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet.

Authors:  C Benoist; D Mathis
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Critical structural elements of the VP16 transcriptional activation domain.

Authors:  W D Cress; S J Triezenberg
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

Review 4.  Transcriptional regulation of the HLA-DRA gene.

Authors:  J P Cogswell; N Zeleznik-Le; J P Ting
Journal:  Crit Rev Immunol       Date:  1991       Impact factor: 2.214

Review 5.  Sequences and factors: a guide to MHC class-II transcription.

Authors:  L H Glimcher; C J Kara
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 6.  MHC class II deficiency: definition of a new complementation group.

Authors:  J Villard; B Mach; W Reith
Journal:  Immunobiology       Date:  1997-12       Impact factor: 3.144

7.  GAL4-VP16 is an unusually potent transcriptional activator.

Authors:  I Sadowski; J Ma; S Triezenberg; M Ptashne
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

8.  A vector for expressing GAL4(1-147) fusions in mammalian cells.

Authors:  I Sadowski; M Ptashne
Journal:  Nucleic Acids Res       Date:  1989-09-25       Impact factor: 16.971

9.  Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).

Authors:  V Steimle; L A Otten; M Zufferey; B Mach
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

10.  The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain.

Authors:  R Marais; J Wynne; R Treisman
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

View more
  16 in total

1.  Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.

Authors:  Krzysztof Masternak; Walter Reith
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

2.  Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.

Authors:  M Peretti; J Villard; E Barras; M Zufferey; W Reith
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

3.  Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.

Authors:  Wojciech Wiszniewski; Marie-Claude Fondaneche; Pascale Louise-Plence; Ada Prochnicka-Chalufour; Françoise Selz; Cappucine Picard; Françoise Le Deist; Jean-François Eliaou; Alain Fischer; Barbara Lisowska-Grospierre
Journal:  Immunogenetics       Date:  2003-01-16       Impact factor: 2.846

4.  New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.

Authors:  Michal Krawczyk; Krzysztof Masternak; Madeleine Zufferey; Emmanuèle Barras; Walter Reith
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

5.  Inhibition of proteasome activity impairs centrosome-dependent microtubule nucleation and organization.

Authors:  Christine Didier; Andreas Merdes; Jean-Edouard Gairin; Nabila Jabrane-Ferrat
Journal:  Mol Biol Cell       Date:  2007-12-19       Impact factor: 4.138

6.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.

Authors:  Suhani Thakker; Pravinkumar Purushothaman; Namrata Gupta; Shanthan Challa; Qiliang Cai; Subhash C Verma
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

7.  Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2.

Authors:  Alyssa Bushey Long; Jeremy M Boss
Journal:  Immunogenetics       Date:  2005-01-18       Impact factor: 2.846

8.  Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.

Authors:  N Nekrep; M Geyer; N Jabrane-Ferrat; B M Peterlin
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

9.  Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.

Authors:  Nabila Jabrane-Ferrat; Nada Nekrep; Giovanna Tosi; Laura J Esserman; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.